| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Sep, 2017 |
| Sales | 1,969,000 | 100 | 140 | 200 | 0 |
| Sales Growth | +1,968,880.31% | -28.57% | -30.00% | unch | unch |
| Net Income | -1,000 | -100 | -90 | -40 | 0 |
| Net Income Growth | -900.00% | -11.11% | -125.01% | unch | unch |
Pixarbio Corp (PXRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
PixarBio Corporation is a specialty pharmaceutical/biotechnology company. It focused on pre-clinical and clinical commercial development of novel neurological drug delivery systems for post-operative pain. The company researches and develops targeted delivery systems for drugs, devices or biologics to treat pain, epilepsy, Parkinson's disease and spinal cord injury. Its product platform includes NeuroRelease(TM). PixarBio Corporation is based in Medford, Massachusetts.
Fiscal Year End Date: 12/31